HUTCHMED (China) Future Growth

Future criteria checks 3/6

HUTCHMED (China) is forecast to grow earnings and revenue by 18.7% and 11.4% per annum respectively. EPS is expected to grow by 21.5% per annum. Return on equity is forecast to be 12.4% in 3 years.

Key information

18.7%

Earnings growth rate

21.5%

EPS growth rate

Pharmaceuticals earnings growth	27.6%
Revenue growth rate	11.4%
Future return on equity	12.4%
Analyst coverage	Good
Last updated	10 Jun 2024

Recent future growth updates

Recent updates

Hutchmed Is Turning Profitable

Mar 20

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Oct 10

Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004

Aug 09

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

Aug 01

Earnings and Revenue Growth Forecasts

NasdaqGS:HCM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,043	98	44	71	14
12/31/2025	849	0	-41	-14	20
12/31/2024	691	-105	-196	-110	19
12/31/2023	838	101	187	219	N/A
9/30/2023	798	36	95	133	N/A
6/30/2023	757	-29	2	48	N/A
3/31/2023	592	-195	-151	-110	N/A
12/31/2022	426	-361	-305	-269	N/A
9/30/2022	414	-308	-276	-246	N/A
6/30/2022	401	-255	-246	-223	N/A
3/31/2022	376	-235	-245	-227	N/A
12/31/2021	356	-195	-221	-204	N/A
9/30/2021	317	-187	-169	-155	N/A
6/30/2021	279	-178	-118	-105	N/A
3/31/2021	258	-151	-95	-83	N/A
12/31/2020	228	-126	-70	-62	N/A
9/30/2020	221	-117	-72	-63	N/A
6/30/2020	209	-110	-88	-79	N/A
3/31/2020	204	-102	-63	-54	N/A
12/31/2019	205	-106	-89	-81	N/A
9/30/2019	205	-93	-86	-77	N/A
6/30/2019	214	-87	-52	-44	N/A
3/31/2019	214	-83	-37	-31	N/A
12/31/2018	214	-75	-39	-33	N/A
9/30/2018	218	-72	-38	-33	N/A
6/30/2018	217	-61	-51	-47	N/A
3/31/2018	230	-39	-54	-49	N/A
12/31/2017	241	-27	-14	-9	N/A
9/30/2017	240	-7	N/A	-4	N/A
6/30/2017	238	13	N/A	1	N/A
3/31/2017	227	12	N/A	-4	N/A
12/31/2016	216	12	N/A	-10	N/A
9/30/2016	200	38	N/A	2	N/A
6/30/2016	200	-8	N/A	-1	N/A
3/31/2016	189	-22	N/A	-5	N/A
12/31/2015	178	-35	N/A	-9	N/A
9/30/2015	168	-80	N/A	-11	N/A
6/30/2015	139	-66	N/A	-6	N/A
3/31/2015	113	-50	N/A	1	N/A
12/31/2014	87	-35	N/A	8	N/A
9/30/2014	72	-20	N/A	11	N/A
6/30/2014	59	7	N/A	21	N/A
3/31/2014	52	8	N/A	13	N/A
12/31/2013	37	26	N/A	5	N/A
9/30/2013	38	10	N/A	0	N/A
6/30/2013	30	13	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HCM's forecast earnings growth (18.7% per year) is above the savings rate (2.4%).

Earnings vs Market: HCM's earnings (18.7% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: HCM's earnings are forecast to grow, but not significantly.

Revenue vs Market: HCM's revenue (11.4% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: HCM's revenue (11.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HCM's Return on Equity is forecast to be low in 3 years time (12.4%).

HUTCHMED (China) Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2022

Recent updates

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Hutchmed Is Turning Profitable

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Inmagene Biopharmaceuticals and HUTCHMED (China) Limited Announce First Participant in Global Phase I Trial of IMG-004

HUTCHMED (China) Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004

HUTCHMED (China) Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic Colorectal Cancer

HUTCHMED (China) Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

HUTCHMED (China) Limited Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83

HUTCHMED (China) Limited Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

Inmagene Biopharmaceuticals and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

Hutchmed, Inmagene begin dosing in early-stage study of IMG-007 for eczema

HUTCHMED (China) Limited to Report First Half, 2022 Results on Aug 01, 2022

HUTCHMED Announces TAZVERIK(R) Approved to be Used in Hainan Pilot Zone in China

HUTCHMED (China) Limited Announces Board Changes

Hutchmed Roils Markets With Changing Of Its Guard, U.S. Delisting Threat

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2022

HUTCHMED (China) Limited Receives Approval to Commercialize Elunate in Macau

HUTCHMED (China) Limited to Report Fiscal Year 2021 Final Results on Mar 03, 2022

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

HUTCHMED (China) Limited Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

HUTCHMED (China) Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquintinib

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

Hutchmed (China) Limited Completes Planned Enrollment of FRESCO-2, A Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

HUTCHMED (China) Limited and AstraZeneca PLC Initiate Sachi Phase III Trial of Orpathys® and Tagrisso® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED (China) Limited and AstraZeneca PLC Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Hutchmed Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer